Pedram Fadavi | Radiation oncology | Best Researcher Award

Posted on by sciencefather

Dr. Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi, M.D., is a distinguished radiation oncologist and associate professor at Iran University of Medical Sciences (IUMS). Born in Tehran, Iran (1974), he specializes in cancer treatment, radiotherapy, and oncological research. With over two decades of experience, he has contributed extensively to academia and clinical practice. His expertise spans breast, head, neck, and gynecologic cancers. He has published influential research in radiomics, chemotherapy delays, and treatment-induced complications. A dedicated educator, he mentors medical students and residents while advancing oncology research. ๐Ÿ“š๐Ÿ’ก

Profile

Education ๐ŸŽ“

Dr. Fadavi earned his M.D. (2000) and board certification in Radiation Oncology (2006) from Shahid Beheshti University, Tehran. He completed a seven-year medical program (1993-2000) and specialized in radiation oncology during his residency (2002-2006). He holds an Iran Medical Council license (No. 76602) and actively contributes to medical education and research at IUMS. His training provided a strong foundation in oncologic treatments and innovative radiotherapy techniques. ๐Ÿ”ฌ๐Ÿ“–

Experience ๐Ÿ‘จโ€๐Ÿซ

Since 2006, Dr. Fadavi has served as a radiation oncologist at Haftome Tir Hospital (IUMS). He became an associate professor in 2008, teaching at IUMS and Tehran University of Medical Sciences (2011-2013). His clinical expertise includes radiotherapy advancements, cancer management, and interdisciplinary oncology research. He has led multiple projects addressing radiation-induced complications and patient outcomes. His leadership in academic and clinical oncology has shaped the future of radiation therapy in Iran. ๐ŸŒ๐Ÿ”ฌ

Research Interests ๐Ÿ”ฌ

Dr. Fadaviโ€™s research centers on radiomics, predictive modeling, and improving radiotherapy outcomes. His recent studies explore machine learning applications in radiation toxicity prediction, chemotherapy delays, and novel treatment strategies for breast, cervical, and head-and-neck cancers. He investigates biomarkers for cancer prognosis and response to therapy, with a strong emphasis on precision oncology. His work in computational oncology and artificial intelligence-driven diagnostics is shaping the future of personalized cancer treatment. ๐Ÿ’ป๐ŸงฌAwards & Recognitions ๐Ÿ…

Dr. Fadavi has received numerous accolades for his contributions to radiation oncology and medical research. His work on radiomics, treatment toxicity, and innovative oncological therapies has been recognized in national and international forums. His publications in leading journals and collaborations with top researchers underscore his impact on global cancer research. He has also been honored for his excellence in medical education, research innovation, and commitment to improving patient care. ๐Ÿ“œ๐Ÿ…

Publications ๐Ÿ“š

Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

Posted on by sciencefather

Prof Dr.ย  Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

: Sun Yat-sen University Fifth Affiliated Hospital, china

Profile

Education

Dr. Hongjun Jin is a Principal Investigator in Nuclear Medicine and a Doctoral Supervisor of Molecular Medicine at Sun Yat-sen University. He earned his PhD in Biochemistry from Texas A&M University in 2007, following a BS in Radiochemistry from Lanzhou University in 1994 and a BMed in Chinese Medicine from Beijing University of Chinese Medicine in 1997. He completed his postdoctoral training at PNNL from 2008 to 2012 and served as a radiology instructor at Washington University in St. Louis from 2012 to 2017. Since 2017, he has led the PET and radiochemical laboratory at his institute, having been recruited through Sun Yat-sen University’s “Hundred Talents Program.”

Research and Innovations:

1) General Research Fund for National Sciences Foundation of China (NSFC), 82372004,
โ€œF-18 labelled PET probe targeting P2X7 receptor for Evaluation of Treatment for ADโ€
01/01/2024-12/31/2027๏ฟฅ480,000,
2) Key R&D project, 0007/2022/AKP, Macao S&T Fund (FDCT),โ€œR&D of an Integrated
Molecular probe for Targeted TNFR2 New Tumor Diagnosis and
Treatmentโ€,01/01/2024-12/31/2027,๏ฟฅ2,400,000 (out of ๏ฟฅ120,000,000)
3) Guangdong Provincial Enterprise Joint Fund, 2021A1515220004, Guangdong Province
โ€œPET/MRI Neuromolecular Imaging Quantitative Study of New Drug Targeting Sigma1

Research Project

  • 1) Outstanding Foreign Young Scientist Talent Program, RFIS, 82150610508 NSF-CN๏ผŒ
    โ€œ Establishment and drug evaluation of acetylcholinergic and dopaminergic
    neuromolecular probes (18F VAT and 18F-DTBZ) PET brain imaging quantitative
    system for Parkinson’s diseaseโ€ 2022/01-2022/12๏ผŒ๏ฟฅ400,000
  • General Research Fund for NSFC, 81871382, โ€œF-18 labelled PET probe targeting P2X7
    receptor for early detection of ADโ€01/01/2019-12/31/2022๏ฟฅ570,000
  • SYSU โ€œHundred Talent โ€œStarting Fund (Period I)โ€ SYSU-FA10/01/2017-09/30/2022
    ๏ฟฅ2,500,000
  • National Key R&D Program for Precision Medicine, 2018YFC0910601 Real-time, highdimensional, multi-modality imaging co-registration and theronoastic strategies for
    oesophageal squamous-cell carcinomas10/01/2018-12/31/2020๏ฟฅ1,272,500 (out of
    ๏ฟฅ19,230,000)
  • Sun Yat-sen University Military Industry Cultivation Project, 89000-18843403 SYSU
    “Key Technologies of Molecular Imaging of Immune Dysfunction in Microgravity
    Environment”, 2019/08-2021/12๏ฟฅ1,890,00
  • Researchers Initiate Clinical Research Project (IIT) Award, SYSU-FAH”A single-center,
    open, prospective assessment of the diagnostic significance of 18F-FDG PET/CT
    dynamic imaging and gene sequencing in detecting metastatic lesions of non-small cell
    lung cancer”,2020/10-2021/09๏ฟฅ50,000
  • COVID-19 infection prevention and control emergency S&T, ZH22036302200036PWC,
    Zhuhai City”Specific Targeting S- protein of SARS-CoV-2 PET molecular imaging
    probe”2020/08-2021/09,๏ฟฅ70,000

Citation Index:

Google Scholar Citations: 8684 (total) 7943 (since 2020)
h-index 26(total) 20 (since 2020)
i10-index 52(total) 39(since 2020)

Publications

Nuo Yu | Radiomics | Best Researcher Award

Posted on by sciencefather

Ms. Nuo Yu | Radiomics | Best Researcher Award

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ,China

Nuo Yu is a Ph.D. candidate at the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences, specializing in radiation oncology with a focus on esophageal squamous cell carcinoma (ESCC). His research primarily explores innovative chemoradiotherapy regimens to improve treatment outcomes for patients with locally advanced ESCC.

Yu has contributed to several peer-reviewed publications in SCI-indexed journals. Notably, he co-authored a study titled “Conversion Chemoradiotherapy Combined with Nab-Paclitaxel Plus Cisplatin in Patients with Locally Advanced Borderline-Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Prospective Cohort Study,” published in Strahlentherapie und Onkologie in August 2024. This research evaluated the efficacy and safety of a novel chemoradiotherapy regimen, demonstrating promising results in locoregional control and overall survival rates.

In March 2023, Yu co-authored another significant study, “Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study,” published in Current Cancer Drug Targets. This research focused on treatment strategies for elderly patients with ESCC, highlighting the potential benefits of combining chemoradiotherapy with nimotuzumab.

Yu’s work has been recognized at international conferences, including presentations at the American Society for Radiation Oncology (ASTRO), the Federation of Asian Organizations for Radiation Oncology (FARO), and the Korean Society for Radiation Oncology (KOSRO). These engagements underscore his active participation in the global radiation oncology community and his commitment to advancing cancer treatment research.

While still in the early stages of his career, Yu’s focused research on ESCC and his contributions to the field of radiation oncology position him as a promising candidate for the Best Researcher Award. Continued efforts to expand his research scope, increase publication impact, and assume leadership roles in larger-scale studies will further strengthen his candidacy.

Profile

Scientific Publications